<SEC-DOCUMENT>0001193125-22-140836.txt : 20220506
<SEC-HEADER>0001193125-22-140836.hdr.sgml : 20220506
<ACCEPTANCE-DATETIME>20220504191437
ACCESSION NUMBER:		0001193125-22-140836
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20220504
FILED AS OF DATE:		20220505
DATE AS OF CHANGE:		20220504

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IMMUTEP Ltd
		CENTRAL INDEX KEY:			0001506184
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			C3
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35428
		FILM NUMBER:		22893358

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 12, 95 PITT STREET
		CITY:			SYDNEY, NEW SOUTH WALES
		STATE:			C3
		ZIP:			2000
		BUSINESS PHONE:		612 9276 1224

	MAIL ADDRESS:	
		STREET 1:		LEVEL 12, 95 PITT STREET
		CITY:			SYDNEY, NEW SOUTH WALES
		STATE:			C3
		ZIP:			2000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Prima BioMed Ltd
		DATE OF NAME CHANGE:	20101119
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d348543d6k.htm
<DESCRIPTION>6-K
<TEXT>
<HTML><HEAD>
<TITLE>6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 6-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE 13a-16 OR 15d-16 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Dated May&nbsp;4, 2022 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number 001-35428 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>IMMUTEP
LIMITED </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact Name as Specified in its Charter) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N/A </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of
Registrant&#146;s Name) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Level 33, Australia Square </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>264 George Street, Sydney </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NSW 2000, Australia </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether
the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form
20-F&nbsp;&nbsp;&#9746;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form 40-F&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the
registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether by furnishing the
information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule&nbsp;12g3-2(b) under the Securities Exchange Act of 1934. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Yes&nbsp;&nbsp;&#9744;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;&#9746; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If &#147;Yes&#148; is marked, indicated below the file number assigned to the registrant in connection with Rule 12g3-2(b): Not applicable. </P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="94%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Exhibit</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Description&nbsp;of&nbsp;Exhibit</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">99.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><B><A HREF="d348543dex991.htm">Immutep presents new and significant data from the AIPAC study </A></B></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: May 4, 2022 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">IMMUTEP LIMITED</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Marc Voigt</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Marc Voigt</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d348543dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g348543g28v83.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ASX/Media Release </B></P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Immutep presents
new and significant data from the AIPAC study </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Statistically significant increase in innate and adaptive immune response biomarkers (monocyte and CD8 T cell
counts and serum CXCL10 levels) and absolute lymphocyte count (ALC) demonstrated in the efti group, but not in the placebo group </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The increase in pharmacodynamic markers is significantly linked to improved OS </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Exploratory analysis identified six patient subgroups with improvements in Overall Survival (OS) which are
relevant for patient population selection for future late-stage studies </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Five of the six patient subgroups show a statistically significant improvement in OS </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SYDNEY, AUSTRALIA &#150; 4 May 2022 &#150;</B> <U>Immutep Limited</U> (ASX: IMM; NASDAQ: IMMP) (&#147;Immutep&#148; or &#147;the Company&#148;), a
biotechnology company developing novel <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">LAG-3-related</FONT></FONT> immunotherapy treatments for cancer and autoimmune disease, today reports new biomarker and exploratory analysis
data from its Phase IIb AIPAC trial. The data was presented at ESMO&#146;s Breast Cancer Congress in a poster presentation which is available on ESMO&#146;s website and at <U>https://www.immutep.com/investors-media/presentations.html</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The double blind and randomised AIPAC trial evaluated efti in combination with paclitaxel chemotherapy (efti group) compared to placebo plus paclitaxel
(placebo group) in 227 patients with HER2-negative/HR positive metastatic breast cancer. Final OS results were reported in November 2021 in a late breaking abstract at SITC showing encouraging efficacy in multiple patient subgroups. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Dr Frederic Triebel, Immutep&#146;s CSO and CMO said:</B> &#147;The biomarker analysis is highly valuable for two key reasons. Firstly, the statistically
significant difference in the immune response between the efti and placebo patients confirms efti is activating the immune system and helping patients live longer. This is demonstrated by the increase in circulating monocytes, CD8 T cells and a
serum Th1 marker, CXCL10, plus the absolute lymphocyte count (ALC), and correlation of these improved immune parameters with overall survival. Secondly, the early rise in ALC in patients treated with efti provides clinicians with a potential
predictor of improved survival, helping them to determine early on if continued treatment with efti is potentially beneficial.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;The
exploratory analysis showing statistically significant improvements in OS in different patient subgroups is also very important as we work towards the optimal design of the planned registrational trial in breast cancer. This all continues to be
consistent with our long-held belief that efti, with its unique mechanism of action, should be able to help diverse sets of patients, including those who fail to respond to current immunotherapy options,&#148; he concluded. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Increase in immune response biomarkers linked to improved overall survival </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Biomarker analysis showed efti, in combination with weekly paclitaxel, significantly increased the number of circulating immune cells (monocytes, activated CD8
T cells) and CXCL10 serum levels, compared to baseline. The increase was not observed in the placebo group (see Table 1). An increase in activated CD4 cells was also observed. The increase in these pharmacodynamic markers (monocytes, CD8 T cells and
CXCL10) was significantly linked to improved OS in the efti group, but not in the placebo group. These findings of an improved immune status are also relevant for the
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> combinations with efti. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g348543g28v83.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notably, in the biomarker study, patient blood samples were drawn 13 days after efti injection. This was to ensure that the study would show the minimum
residual pharmacodynamic effect from therapy with efti and paclitaxel, since efti disappears from the blood in only <FONT STYLE="white-space:nowrap">3-4</FONT> days. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Thus, since efti is administered every 14 days, we conclude that that the observed increase in the number of circulating immune cells was sustained throughout
the course of treatment (or even greater at the peak of the immune response). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Potential predictive biomarker for improved survival </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The absolute lymphocyte count (ALC) was shown to increase early and sustainably in patient&#146;s treatment regimen in the efti group, but not the placebo
group. The increase in ALC was also significantly linked to improved OS. ALC can be measured easily in every hospital laboratory, making it a practical potential predictive biomarker for efti efficacy and therefore improved survival. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Table 1. Immune response biomarkers compared to placebo </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="26%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="22%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="22%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="21%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Biomarker</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Treatment</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Fold&nbsp;change&nbsp;mean&nbsp;&plusmn;<BR>SEM<BR></B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Median</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">p-value</FONT><BR></B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">(2-sided&nbsp;rank-sum</FONT></FONT><BR>Wilcoxon test)</B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" ROWSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Monocytes</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center">Efti&nbsp;(n&nbsp;=&nbsp;42)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5.81&nbsp;&plusmn;&nbsp;1.49</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2.07</P></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ROWSPAN="2" NOWRAP ALIGN="center">0.025</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center">Placebo&nbsp;(n&nbsp;=&nbsp;34)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2.29&nbsp;&plusmn;&nbsp;0.44</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1.47</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" ROWSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Activated CD8 T cells</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center">Efti&nbsp;(n&nbsp;=&nbsp;42)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2.54&nbsp;&plusmn;&nbsp;0.35</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1.76</P></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ROWSPAN="2" NOWRAP ALIGN="center">0.027</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center">Placebo (n = 34)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1.86 &plusmn; 0.40</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1.17</P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" ROWSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CXCL10</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center">Efti&nbsp;(n&nbsp;=&nbsp;32)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2.78&nbsp;&plusmn;&nbsp;0.30</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2.39</P></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ROWSPAN="2" NOWRAP ALIGN="center">0.006</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center">Placebo (n = 22)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1.56&nbsp;&plusmn;&nbsp;0.18</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1.40</P></TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Univariate and multivariate analysis indicates subgroups for future studies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Through exploratory analyses, six subgroups of patients showed an improvement in OS in the efti group, compared to placebo (see Table 2). Five of the six
subgroups (&lt; 65 years, low baseline monocytes, high neutrophil to lymphocyte ratio (NLR), &lt; 5 years since diagnosis and luminal B) showed a statistically significant improvement in OS and in the &#145;no prior taxane therapy subgroup&#146; a
statistically significant increase was also seen in ORR. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The subgroups will be considered for patient population selection for future studies, such as
Immutep&#146;s planned Phase III <FONT STYLE="white-space:nowrap">AIPAC-003</FONT> trial. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g348543g28v83.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Multivariate analysis showed patients entering the trial with high body mass index (BMI) and prior CDK4/6 treatment had significantly poorer PFS and OS
outcomes irrespective of the therapy they received. High BMI and prior CDK4/6 treatment are therefore considered independent poor prognostic markers and will be considered as stratification factors for future studies. Multivariate analysis also
showed that low monocytes and no prior taxane therapy were independent significant predictive factors for improved OS. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Table 2. Six favourable
subgroups with improved OS based on univariate analysis </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="50%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="75%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Subgroup</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Absolute&nbsp;gain&nbsp;in&nbsp;median<BR>Overall Survival<BR>(months) (hazard ratio,<BR>p value)</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>&lt; 65 years</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">+7.5&nbsp;(0.66,&nbsp;0.017)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Low baseline monocytes</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">+19.6&nbsp;(0.44,&nbsp;0.008)</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>High neutrophil to lymphocyte ratio (NLR)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">+6.9&nbsp;(0.61,&nbsp;0.012)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>&lt; 5 years since diagnosis</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">+4.8 (0.62, 0.025)</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Luminal B</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">+4.2 (0.67, 0.049)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>No prior taxane therapy</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">+4.8 (0.74, 0.076)</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About the AIPAC Trial </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Active Immunotherapy Paclitaxel (AIPAC) was a multicentre, placebo-controlled, double-blind, 1:1 randomised&nbsp;Phase IIb clinical trial in HER2-negative/HR
positive metastatic breast cancer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The study evaluated the combination of Immutep&#146;s lead product candidate, eftilagimod alpha (efti, <FONT
STYLE="white-space:nowrap">LAG-3Ig</FONT> or IMP321), and paclitaxel chemotherapy. 227 HER2-negative/HR positive metastatic breast cancer patients were randomised 1:1 to a chemo-immunotherapy arm (efti plus paclitaxel) or to a comparator arm
(placebo plus paclitaxel). Patients received weekly paclitaxel at days 1, 8 and 15, with either efti or placebo injected subcutaneously on days 2 and 16 of each <FONT STYLE="white-space:nowrap">4-week</FONT> cycle, repeated for 6 cycles. Thereafter,
patients passed over to the maintenance phase with efti alone. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For more information regarding the AIPAC trial, visit clinicaltrials.gov (identifier
NCT02614833) and <U>https://www.ncbi.nlm.nih.gov/pubmed/30977393.</U> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Immutep </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immutep is a globally active biotechnology company that is a leader in the development of <FONT STYLE="white-space:nowrap">LAG-3</FONT> related
immunotherapeutic products for the treatment of cancer and autoimmune disease. Immutep is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximize value to shareholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immutep&#146;s current lead product candidate is eftilagimod alpha (&#147;efti&#148; or &#147;IMP321&#148;), a soluble
<FONT STYLE="white-space:nowrap">LAG-3</FONT> fusion protein <FONT STYLE="white-space:nowrap">(LAG-3Ig),</FONT> which is a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> antigen presenting cell (APC)
activator being explored in cancer and </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g348543g28v83.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">infectious disease. Immutep is also developing an agonist of <FONT STYLE="white-space:nowrap">LAG-3</FONT> (IMP761) for autoimmune disease. Additional <FONT
STYLE="white-space:nowrap">LAG-3</FONT> products, including antibodies for immune response modulation, are being developed by Immutep&#146;s large pharmaceutical partners. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immutep is listed on the Australian Securities Exchange (IMM), and on the NASDAQ (IMMP) in the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further information can be found on the Company&#146;s website <U>www.immutep.com</U> or by contacting: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Australian Investors/Media: </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Catherine Strong,
Citadel-MAGNUS </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+61 (0)406 759 268; <U>cstrong@citadelmagnus.com</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>U.S. Media: </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Tim McCarthy, LifeSci Advisors </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+1 (212) 915.2564;&nbsp;<U>tim@lifesciadvisors.com</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This
announcement was authorised for release by the Board of Immutep Limited. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Immutep Limited</B>, Level 33, Australia Square </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">264 George Street, Sydney NSW 2000 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ABN: 90 009 237 889 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g348543g28v83.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g348543g28v83.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M P$  A$#$0 _ /W\H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* #I^% "%@.^,<^F/\XH_0&^7RL?#7QA^,?B;4WO[+PA)J.E^$M-U*;0;SQ'
M92-%_:NKHOFM!::E"C?9[=(2VP0OYDH!D+!0JUX>.Q=6HHQP\'&*WES):_)W
MMY'Y]G6=XNK)QR_F>'IOEG4C+E7-JTK/E;TUT3\^AY1X<@^(%QJ?AX6?B/Q/
MI.H:WJ<MO:S7<NO16Z6EO;P7,NK2WC'9?:>BNQD"A@!$_F,H89X,.L4G?VKT
M\Y+\SQ,%3S6I4H_[=/#5IREK/VW*XK6UU>VG>R/M+X?_ !">YU;6/ WB75]/
MU3Q'X<ACN'U[3E6+2]:LI1:L)41?DM;ZW:\@AFA0E"2'0\LJ>UA\7%RE2JU5
MS02[_G:WW,^]P.:TZ=2I@<574JV&C%RJZ\DV]+*^MU_6S.@\/_%_X<^*?$=]
MX3\.^*M.U77].2Z>XL;<72@BPD\F_%M=S0);7C6\I42""63;U. "5]$]\]+H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H 0]*$"*.H132V-Y%;M
MMFDM+F.$_P!V5HI%B/X.5_*GM\B9_=8_,/P%XANO#GB#1]*UZ:[7PXNN0OX@
MT&>(W-K-<(PLF>YTV6.1&NH+B*W8LJ*^+< 'C!^0HU_JE50Q+O%]'_D?C&65
MJE/%QP^)J<N&I55*I1E9M.UDY)Z[)K4^O/C!XQ\"ZMX*U?PS;>)]%GU;5$AM
M].M[2^%P([F.[@Q]JEL/-6QMLHT;M<&./#%6.#BO:Q6)PKHN%#EY]&N7='Z%
MGN,RZM@7A:&84(8J4E[%P<>:*B[M*VUHIIGQSX<\*>*[KQ)J6B^'C'_:NF6U
MT+J33Y%O;86T5Y;12K%<6\A1HVG>#!5L-Y)X^4UXV%E>K5CO.*U^\_/:5#'O
M$5*5*K*M5IQ7/-.[>O?R/KCX=_L\> _ /Q!NO'.B:[J=]J,@U;[+I5U>:=);
MV']J[S<2 VUG'-<E(YIT1)'*QB=R2[?-7U<)PD^5/6)^S1JTI2Y*<TWNU=/]
M=/0^E)+J"!=TLBPH ?GD^2, $@[G8A5Z=2:)RA"T9-+RN5-JEK.I&'^)I+OU
M:U,IO$_AQ'$3:_HBR'A8VU2P5SVX0W.>M0JM'1<R_P# E_F8_6:"_P"8JCIT
MYX__ "1K)<1.@DCDC:(C<LJNIC*C^(.#M*^X.*ULE]I*W0V4Z3CSJI&WJO\
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MN=/UC3)9)HQ<(P\N1B79!/'- Z<X-@V/M+]I?7UU7]GFY\0:5//;P:R?!M]
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M?K7MX>/)0I1O\4(V_P# ;GW&6+_A/P<>5)JE3VVT@CX>L%\O]I!P. OQ%U'
M';.H7K']6KP:<YO,XPB[)5.7_P !O?\ (_.8P<>,)57*T(XN226^[6VBZGVC
M\3E#?#OQJI ('AG62,]F2PG=3^!(_*O=Q,FL/6[)27X'Z'FJ3RW&\]VHT)M=
M[\DK/IY'S'^R@<:KXT7M_9NA_F+G4 /YUY&1/7$]+*/_ +<?'\#\L*F.4')K
MEPVDNCM6VU>YQ7BG_DX\?]CYX9_]&Z-6-1I9FKWM[1;;]#S<PD_];E&"7-]8
MHI<VVLJ2??IY'W3XN0GPIXD4A67_ (1W6]RMW_XEEQCM[FO?KJ+HUMU[C_\
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1YQ@@DV#8^QJ "@ H * /_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
